Lakewood‑Amedex presents preclinical data on Nu‑3 antimicrobial at IDWeek 2026
Lakewood‑Amedex Biotherapeutics disclosed preclinical results for its lead candidate Nu‑3 at the IDWeek 2026 conference. The data show rapid, broad‑spectrum bactericidal activity against Gram‑positive, Gram‑negative and multidrug‑resistant pathogens, with minimal increase in MIC values after serial passage. Nu‑3 is being evaluated in a Phase 2a trial for mildly infected diabetic foot ulcers, with topline results expected in the first quarter of 2027.
Why it matters
The company says the data reinforce Nu‑3’s potential to address antimicrobial‑resistance challenges, which could improve investor sentiment ahead of the Phase 2a readout. The upcoming Q1 2027 topline data will be a key catalyst for the stock.
Key facts
- 1Lakewood‑Amedex presented Nu‑3 data at IDWeek 2026, held October 21‑24, 2026 in Washington, D.C. prnewswire.com
- 2Nu‑3 demonstrated rapid bactericidal activity, eradicating tested bacteria within minutes and showing activity against biofilm organisms. prnewswire.com
- 3Serial‑passage testing showed only a slight increase in MIC values for Staphylococcus aureus and Escherichia coli, compared with a 600‑ to 2,000‑fold increase for ciprofloxacin. prnewswire.com
- 4Nu‑3 is in an ongoing Phase 2a trial for mildly infected diabetic foot ulcers. prnewswire.com
- 5Topline data from the Phase 2a trial are expected in the first quarter of 2027. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.